Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Queen's University at Kingston

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1841-10-16

Employees: 1K

Market Cap: -

Website: http://www.queensu.ca

Clinical Trials

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Phase 2

Active, not recruiting

Conditions: Oropharyngeal Squamous Cell Carcinoma

Interventions: Radiation: Radiation
Drug: Durvalumab
Drug: Cisplatin
Drug: Tremelimumab

First Posted Date: 2018-01-25

Last Posted Date: 2025-01-09

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 129

Registration Number: NCT03410615

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪
University Hospital of Antwerp, Edegem, Belgium
🇧🇪
University Hospital of Gent, Gent, Belgium

and more 23 locations

Prostate Cancer Biomarker Enrichment and Treatment Selection

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Savolitinib
Drug: Darolutamide
Drug: Durvalumab and Tremelimumab
Drug: CFI-400945
Drug: Adavosertib
Drug: Ipatasertib
Drug: Carboplatin

First Posted Date: 2017-12-28

Last Posted Date: 2025-03-17

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 200

Registration Number: NCT03385655

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada

and more 8 locations

The Montreal Neighbourhood Networks and Healthy Aging Panel

Conditions: Hypertension
Health Behavior
Obesity
Depression
Subjective Health
Physical Activity

Interventions: Other: Social capital; Neighborhood environment

First Posted Date: 2017-12-12

Last Posted Date: 2019-01-11

Lead Sponsor: Queen's University

Target Recruit Count: 2707

Registration Number: NCT03369496

Determining the Impact of a New Physiotherapist Led Primary Care Model for Back Pain

Not Applicable

Completed

Conditions: Back Pain

Interventions: Other: Usual care
Behavioral: Physiotherapist-led primary care model for back pain

First Posted Date: 2017-10-25

Last Posted Date: 2019-03-25

Lead Sponsor: Queen's University

Target Recruit Count: 100

Registration Number: NCT03320148

Locations: 🇨🇦
Queen's University, Kingston, Ontario, Canada

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase 2

Recruiting

Conditions: Lymphoma, Non-Hodgkin
Multiple Myeloma
Advanced Solid Tumors

Interventions: Drug: Erlotinib
Drug: Dasatinib
Drug: Axitinib
Drug: Bosutinib
Drug: Crizotinib
Drug: Nivolumab plus Ipilimumab
Drug: Olaparib
Drug: Palbociclib
Drug: Sunitinib
Drug: Temsirolimus
Drug: Trastuzumab plus Pertuzumab
Drug: Vemurafenib plus Cobimetinib
Drug: Vismodegib
Drug: Tucatinib

First Posted Date: 2017-09-29

Last Posted Date: 2025-03-11

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 720

Registration Number: NCT03297606

Locations: 🇨🇦
London Health Sciences Centre Research Inc., London, Ontario, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada

and more 7 locations

Effects of Probiotics on Symptoms of Depression

Phase 3

Terminated

Conditions: Anxiety
Depression

Interventions: Drug: Probio'Stick
Drug: Placebo

First Posted Date: 2017-09-11

Last Posted Date: 2024-10-17

Lead Sponsor: Dr. Roumen Milev

Target Recruit Count: 28

Registration Number: NCT03277586

Locations: 🇨🇦
Providence Care Hospital, Kingston, Ontario, Canada

NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: Folfox Protocol
Drug: Capox

First Posted Date: 2017-08-23

Last Posted Date: 2024-10-10

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 58

Registration Number: NCT03259035

Locations: 🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States

and more 8 locations

Evaluation of Bowel Sensitivity Threshold in IBS Patients Versus in Healthy Controls Using the Novel Rapid Barostat Bag

Not Applicable

Conditions: Irritable Bowel Syndrome
Visceral Hypersensitivity

Interventions: Device: Rapid Barostat Bag
Other: IBS severity scoring system questionnaire (IBS-SSS)
Other: HAD scale questionnaire

First Posted Date: 2017-07-21

Last Posted Date: 2017-10-04

Lead Sponsor: Queen's University

Target Recruit Count: 200

Registration Number: NCT03224494

Locations: 🇨🇦
Kingston Health Sciences Centre - HDH site, Kingston, Ontario, Canada

Effect of FODMAPs on Mucosal Inflammation in IBS Patients

Not Applicable

Conditions: Irritable Bowel Syndrome With Diarrhea

Interventions: Other: Low FODMAP Diet followed by a High FODMAP Diet

First Posted Date: 2017-07-19

Last Posted Date: 2017-10-05

Lead Sponsor: Queen's University

Target Recruit Count: 20

Registration Number: NCT03221790

Bupivacaine Levels in Liver Resection Patients

Completed

Conditions: Hepatectomy
Analgesia, Epidural

First Posted Date: 2017-05-09

Last Posted Date: 2025-03-24

Lead Sponsor: Jessica Burjorjee, MD, FRCPC

Target Recruit Count: 20

Registration Number: NCT03145805

Locations: 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy